Cefepime vs. Carbapenems for Treating AmpC β-lactamase-producing Enterobacteriaceae Bloodstream Infections (CARBAPENEM)

University Hospital, Strasbourg, France

Status: Completed

Conditions: Bacteremia

Study type: Observational

Funder types: Other

Identifiers

NCT05535751

8660

Details and patient eligibility

About

Recent international recommendations suggest the use of carbapenem rather than cefepime in this situation, but with a low level of evidence, given the few existing studies. As cefepime is a less broad-spectrum antibiotic than carbapenems, its use would limit the selection of multidrug-resistant bacteria.

Enrollment: 200 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patient (≥18 years of age)
• managed within a study center for high-grade cephalosporinase-producing bacteremia
• Not objecting to the reuse of their health data for scientific research purposes.

Exclusion criteria

• Patient who has expressed opposition to the reuse of their data for scientific research purposes.
• Resistance to Cefepime or carbapenems
• Multiple bacteremia
• Treatment with a molecule other than Cefepime or carbapenem.